Adriamycin-associated cardiomyopathy

where are we now? updates in pathophysiology, dose recommendations, prognosis, and outcomes

Research output: Contribution to journalArticle

Abstract

PURPOSE OF REVIEW: Advances in cancer treatments have resulted in significant improvements in survival. Anthracycline chemotherapeutics play a major role in the treatment of hematologic malignancies and solid tumors; however, there is a risk of anthracycline cardiomyopathy in survivors. This focused review will provide a historical context on anthracycline cardiomyopathy and will also review pathophysiologic mechanisms of cardiotoxicity, dosage recommendations, prognosis, and outcomes. RECENT FINDINGS: Anthracycline inhibition of topoisomerase 2β in cardiomyocytes is believed to be the dominant mechanism of anthracycline-related cardiotoxicity. Emerging data suggest that downregulation of the RNA-binding protein quaking 5 may also be contributing. There is continued lack of agreement regarding what dosage of anthracycline is associated with the highest risk of cardiotoxicity. SUMMARY: Ongoing research into the mechanisms of anthracycline cardiotoxicity is warranted to allow for the development of targeted preventive therapies. A consensus definition of anthracycline cardiomyopathy will facilitate analyses of existing data and allow for the conduction of prospective clinical trials in this area.

Original languageEnglish (US)
Pages (from-to)289-295
Number of pages7
JournalCurrent opinion in cardiology
Volume34
Issue number3
DOIs
StatePublished - May 1 2019

Fingerprint

Anthracyclines
Cardiomyopathies
Doxorubicin
RNA-Binding Proteins
Hematologic Neoplasms
Cardiac Myocytes
Neoplasms
Down-Regulation
Clinical Trials
Cardiotoxicity
Research

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{345f33bcb4c4483bb8dddd7fa0f4d636,
title = "Adriamycin-associated cardiomyopathy: where are we now? updates in pathophysiology, dose recommendations, prognosis, and outcomes",
abstract = "PURPOSE OF REVIEW: Advances in cancer treatments have resulted in significant improvements in survival. Anthracycline chemotherapeutics play a major role in the treatment of hematologic malignancies and solid tumors; however, there is a risk of anthracycline cardiomyopathy in survivors. This focused review will provide a historical context on anthracycline cardiomyopathy and will also review pathophysiologic mechanisms of cardiotoxicity, dosage recommendations, prognosis, and outcomes. RECENT FINDINGS: Anthracycline inhibition of topoisomerase 2β in cardiomyocytes is believed to be the dominant mechanism of anthracycline-related cardiotoxicity. Emerging data suggest that downregulation of the RNA-binding protein quaking 5 may also be contributing. There is continued lack of agreement regarding what dosage of anthracycline is associated with the highest risk of cardiotoxicity. SUMMARY: Ongoing research into the mechanisms of anthracycline cardiotoxicity is warranted to allow for the development of targeted preventive therapies. A consensus definition of anthracycline cardiomyopathy will facilitate analyses of existing data and allow for the conduction of prospective clinical trials in this area.",
author = "Brian Hardaway",
year = "2019",
month = "5",
day = "1",
doi = "10.1097/HCO.0000000000000617",
language = "English (US)",
volume = "34",
pages = "289--295",
journal = "Current Opinion in Cardiology",
issn = "0268-4705",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Adriamycin-associated cardiomyopathy

T2 - where are we now? updates in pathophysiology, dose recommendations, prognosis, and outcomes

AU - Hardaway, Brian

PY - 2019/5/1

Y1 - 2019/5/1

N2 - PURPOSE OF REVIEW: Advances in cancer treatments have resulted in significant improvements in survival. Anthracycline chemotherapeutics play a major role in the treatment of hematologic malignancies and solid tumors; however, there is a risk of anthracycline cardiomyopathy in survivors. This focused review will provide a historical context on anthracycline cardiomyopathy and will also review pathophysiologic mechanisms of cardiotoxicity, dosage recommendations, prognosis, and outcomes. RECENT FINDINGS: Anthracycline inhibition of topoisomerase 2β in cardiomyocytes is believed to be the dominant mechanism of anthracycline-related cardiotoxicity. Emerging data suggest that downregulation of the RNA-binding protein quaking 5 may also be contributing. There is continued lack of agreement regarding what dosage of anthracycline is associated with the highest risk of cardiotoxicity. SUMMARY: Ongoing research into the mechanisms of anthracycline cardiotoxicity is warranted to allow for the development of targeted preventive therapies. A consensus definition of anthracycline cardiomyopathy will facilitate analyses of existing data and allow for the conduction of prospective clinical trials in this area.

AB - PURPOSE OF REVIEW: Advances in cancer treatments have resulted in significant improvements in survival. Anthracycline chemotherapeutics play a major role in the treatment of hematologic malignancies and solid tumors; however, there is a risk of anthracycline cardiomyopathy in survivors. This focused review will provide a historical context on anthracycline cardiomyopathy and will also review pathophysiologic mechanisms of cardiotoxicity, dosage recommendations, prognosis, and outcomes. RECENT FINDINGS: Anthracycline inhibition of topoisomerase 2β in cardiomyocytes is believed to be the dominant mechanism of anthracycline-related cardiotoxicity. Emerging data suggest that downregulation of the RNA-binding protein quaking 5 may also be contributing. There is continued lack of agreement regarding what dosage of anthracycline is associated with the highest risk of cardiotoxicity. SUMMARY: Ongoing research into the mechanisms of anthracycline cardiotoxicity is warranted to allow for the development of targeted preventive therapies. A consensus definition of anthracycline cardiomyopathy will facilitate analyses of existing data and allow for the conduction of prospective clinical trials in this area.

UR - http://www.scopus.com/inward/record.url?scp=85064721732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064721732&partnerID=8YFLogxK

U2 - 10.1097/HCO.0000000000000617

DO - 10.1097/HCO.0000000000000617

M3 - Article

VL - 34

SP - 289

EP - 295

JO - Current Opinion in Cardiology

JF - Current Opinion in Cardiology

SN - 0268-4705

IS - 3

ER -